US 8835613
β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
granted A61KA61K2039/585A61K31/7004
Quick answer
US patent 8835613 (β-mannosylceramide and stimulation of NKT cell anti-tumor immunity) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/585, A61K31/7004, A61K31/7032, A61K38/2013